{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T09:06:09Z","timestamp":1788339969401,"version":"build-2803163510"},"reference-count":30,"publisher":"Elsevier BV","issue":"15","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T00:00:00Z","timestamp":1721606400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020410","name":"Health Institutes of Turkey","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020410","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.heliyon.2024.e35020","type":"journal-article","created":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T03:22:22Z","timestamp":1721704942000},"page":"e35020","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Repurposing of known drugs from multiple libraries to identify novel and potential selective inhibitors of HDAC6 via in silico approach and molecular modeling"],"prefix":"10.1016","volume":"10","author":[{"given":"Naz Mina","family":"Mert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Buse","family":"Erdogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0052-4926","authenticated-orcid":false,"given":"Kemal","family":"Yelek\u00e7i","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.heliyon.2024.e35020_bib1","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/carcin\/bgp220","article-title":"Epigenetics in cancer","volume":"31","author":"Sharma","year":"2009","journal-title":"Carcinogenesis"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e35020_bib2","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/med.20024","article-title":"Histone deacetylation in epigenetics: an attractive target for anticancer therapy","volume":"25","author":"Mai","year":"2005","journal-title":"Med. Res. Rev."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e35020_bib3","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/bfgp\/elx018","article-title":"Epigenetic regulation of gene expression in cancer: techniques, resources and analysis","volume":"17","author":"Kagohara","year":"2018","journal-title":"Briefings in Functional Genomics"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e35020_bib4","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/sj.cr.7310149","article-title":"HDACs, histone deacetylation, and gene transcription: from molecular biology to cancer therapeutics","volume":"17","author":"Gallinari","year":"2007","journal-title":"Cell Res."},{"issue":"10","key":"10.1016\/j.heliyon.2024.e35020_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1101\/cshperspect.a026831","article-title":"HDACs and HDAC inhibitors in cancer development and therapy","volume":"6","author":"Li","year":"2016","journal-title":"Cold Spring Harbor Perspectives in Medicine"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e35020_bib6","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/nchembio.313","article-title":"Chemical phylogenetics of histone deacetylases","volume":"6","author":"Bradner","year":"2010","journal-title":"Nat. Chem. Biol."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e35020_bib7","first-page":"241","article-title":"Computational studies on the histone deacetylases and the design of selective histone deacetylase inhibitors","volume":"9","author":"Wang","year":"2009"},{"issue":"10","key":"10.1016\/j.heliyon.2024.e35020_bib8","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1038\/nrd2681","article-title":"Therapeutic application of histone deacetylase inhibitors for central nervous system disorders","volume":"7","author":"Kazantsev","year":"2008","journal-title":"Nat. Rev. Drug Discov."},{"issue":"6887","key":"10.1016\/j.heliyon.2024.e35020_bib9","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/417455a","article-title":"HDAC6 is a microtubule-associated deacetylase","volume":"417","author":"Hubbert","year":"2002","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e35020_bib10","doi-asserted-by":"crossref","DOI":"10.1186\/1750-1326-8-7","article-title":"HDAC6 as a target for neurodegenerative diseases: what makes it different from the other HDACs?","volume":"8","author":"Sim\u00f5es-Pires","year":"2013","journal-title":"Mol. Neurodegener."},{"issue":"31","key":"10.1016\/j.heliyon.2024.e35020_bib12","doi-asserted-by":"crossref","first-page":"10842","DOI":"10.1021\/ja102758v","article-title":"Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, tubastatin A","volume":"132","author":"Butler","year":"2010","journal-title":"J. Am. Chem. Soc."},{"issue":"12","key":"10.1016\/j.heliyon.2024.e35020_bib13","doi-asserted-by":"crossref","first-page":"3231","DOI":"10.1080\/07391102.2017.1384402","article-title":"Identification of potential isoform-selective histone deacetylase inhibitors for cancer therapy: a combined approach of structure-based virtual screening, admet prediction and molecular dynamics simulation assay","volume":"36","author":"Uba","year":"2018","journal-title":"J. Biomol. Struct. Dyn."},{"issue":"11","key":"10.1016\/j.heliyon.2024.e35020_bib14","first-page":"4358","volume":"7","author":"Porwal","year":"2016","journal-title":"Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma"},{"issue":"8","key":"10.1016\/j.heliyon.2024.e35020_bib15","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1517\/13543784.2011.594437","article-title":"Romidepsin: a novel histone deacetylase inhibitor for cancer","volume":"20","author":"Bertino","year":"2011","journal-title":"Expet Opin. Invest. Drugs"},{"issue":"21","key":"10.1016\/j.heliyon.2024.e35020_bib16","doi-asserted-by":"crossref","first-page":"4767","DOI":"10.1158\/1078-0432.CCR-15-0530","article-title":"Panobinostat for the treatment of multiple myeloma","volume":"21","author":"Laubach","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.heliyon.2024.e35020_bib17","article-title":"Spiroindoline-capped selective HDAC6 inhibitors: design, synthesis, structural analysis, and biological evaluation","volume":"8","author":"Saraswati","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"issue":"15","key":"10.1016\/j.heliyon.2024.e35020_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.21037\/atm.2016.07.22","article-title":"Histone deacetylase inhibitors as cancer therapeutics","volume":"4","author":"Clawson","year":"2016","journal-title":"Ann. Transl. Med."},{"issue":"9","key":"10.1016\/j.heliyon.2024.e35020_bib19","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/nchembio.2134","article-title":"Histone deacetylase 6 structure and molecular basis of catalysis and inhibition","volume":"12","author":"Hai","year":"2016","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.heliyon.2024.e35020_bib20","series-title":"BIOVIA Discovery Studio 2017 R2: A Comprehensive Predictive Science Application for the Life Sciences","author":"Biovia","year":"2017"},{"issue":"11","key":"10.1016\/j.heliyon.2024.e35020_bib21","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1021\/acs.jcim.5b00559","article-title":"Zinc 15 - ligand discovery for everyone","volume":"55","author":"Sterling","year":"2015","journal-title":"J. Chem. Inf. Model."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e35020_bib22","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jcc.21334","article-title":"AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading","volume":"31","author":"Trott","year":"2010","journal-title":"J. Comput. Chem."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e35020_bib23","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.ddtec.2004.11.007","article-title":"Lead- and druglike compounds: the rule-of-five revolution","volume":"1","author":"Lipinski","year":"2004","journal-title":"Drug Discov. Today Technol."},{"issue":"16","key":"10.1016\/j.heliyon.2024.e35020_bib24","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1002\/jcc.20289","article-title":"Scalable molecular dynamics with NAMD","volume":"26","author":"Phillips","year":"2005","journal-title":"J. Comput. Chem."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e35020_bib25","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1021\/acs.jctc.5b00935","article-title":"CHARMM-GUI input generator for NAMD, GROMACS, AMBER, OpenMM, and CHARMM\/OpenMM simulations using the CHARMM36 additive force field","volume":"12","author":"Lee","year":"2016","journal-title":"J. Chem. Theor. Comput."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e35020_bib26","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.neuron.2018.08.011","article-title":"Molecular dynamics simulation for all","volume":"99","author":"Hollingsworth","year":"2018","journal-title":"Neuron"},{"issue":"24","key":"10.1016\/j.heliyon.2024.e35020_bib27","doi-asserted-by":"crossref","first-page":"6298","DOI":"10.1073\/pnas.1700919114","article-title":"Structural basis for ligand binding to an enzyme by a conformational selection pathway","volume":"114","author":"Kovermann","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e35020_bib28","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.bpj.2009.11.011","article-title":"Determination of ensemble-average pairwise root mean-square deviation from experimental B-factors","volume":"98","author":"Kuzmanic","year":"2010","journal-title":"Biophys. J."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e35020_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0119264","article-title":"Automatic identification of mobile and rigid substructures in molecular dynamics simulations and fractional structural fluctuation analysis","volume":"10","author":"Mart\u00ednez","year":"2015","journal-title":"PLoS One"},{"issue":"20","key":"10.1016\/j.heliyon.2024.e35020_bib30","doi-asserted-by":"crossref","first-page":"11849","DOI":"10.1021\/acsomega.0c01818","article-title":"Therapeutic potential of Quercetin: new insights and perspectives for human Health","volume":"5","author":"Salehi","year":"2020","journal-title":"ACS Omega"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e35020_bib31","first-page":"1","article-title":"Structural and free energy landscape of novel mutations in ribosomal protein S1 (rpsA) associated with pyrazinamide resistance","volume":"9","author":"Khan","year":"2019","journal-title":"Sci. Rep."}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024110511?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024110511?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T21:49:13Z","timestamp":1784065753000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844024110511"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":30,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S2405844024110511"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e35020","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Repurposing of known drugs from multiple libraries to identify novel and potential selective inhibitors of HDAC6 via in silico approach and molecular modeling","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e35020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e35020"}}